TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04442633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutamine Cap/Tab
Description: Glutamine Capsules: One capsule three times daily on an empty stomach for one month

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Oral gel
Description: Miconazole oral gel: applied three to four times daily for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Oral gel
Description: Miconazole oral gel: applied three to four times daily for three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kenacort in orabase
Description: Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kenacort in orabase
Description: Kenacort in orabase: applied two to three times a day for 3 weeks followed by tapering the following 9 weeks until a maintenance dose of two to three times a week is reached
Study: NCT04961346

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrapro® mesh
Description: large-pore, lightweight polypropylene mesh

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Premilene® mesh
Description: small-pore, heavyweight polypropylene mesh
Study: NCT01901289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX® Drug-Eluting Peripheral Stent
Description: Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
Study: NCT01763853

Intervention type: DRUG
Group type: OTHER
Intervention: 4% albumin

Intervention type: DRUG
Group type: OTHER
Intervention: 4% albumin
Study: NCT04132141

Intervention type: OTHER
Group type: OTHER
Intervention: Virtual Reality Headset with curated content
Description: clinicians will wear VR immersive headset for up to 15 minutes during their break
Study: NCT01340066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UISH001
Description: sublingual dosing, 1 drop 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matching placebo
Description: sublingual dosing,1 drop 3 times a day
Study: NCT00578916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVRI (BMS-690514)
Description: Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
Study: NCT02789020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.
Study: NCT01144416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 900962 / Corifollitropin alfa / Org 36286
Description: SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RecFSH / follitropin beta
Description: RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for SCH 900962
Description: Supplied as a pre-filled syringe containing an identical solution when~compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for recFSH
Description: Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
Study: NCT02595866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiretroviral Therapy
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT01072136

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
Study: NCT01294111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
Study: NCT00062491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Karenitecin (BNP1350)
Description: Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR\< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
Study: NCT00319202

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candesartan
Description: 32 mg/d for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administration for 6 months
Study: NCT05129163

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The group exercise training was held in each community center. The group exercise training contained aerobic exercise, complex physical fitness exercise, muscle training, and balance and coordination training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition activities
Description: The intervention programs included: (a) training on-site staffs to use motivational interview techniques to communicate, to estimate participant's energy requirements, and to learn how to provide proper amounts of foods to individual elderlies, (b) nutrition grouped activities on ①know my plate, ②wholegrains, ③ drinking teas with dairy, and nuts, ④novel ways to eat fruit and vegetables, ⑤healthy breakfast ideas. In the first month, participants were intervened with the activities laid out above; in the second month, participants were intervened with qualitative discussion on elders' dietary changes; in the third month, participants were intervened with designed activities that helped break down barriers in order to establish a long-term change in dietary habits.
Study: NCT01744067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: 2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules 3 times a day (oral administration)
Study: NCT01878578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate
Description: Tablets containing ESL 600 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phenytoin
Description: Hidantina® tablets containing 100 mg of phenytoin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets containing matching placebo
Study: NCT01779336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL225B
Description: * Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified.
Study: NCT00873821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
Study: NCT03776318

Intervention type: DRUG
Intervention: Long-Term Safety Follow-up
Description: STX-015-18-01 long-term safety follow-up

Intervention type: DRUG
Intervention: Long-Term Safety Follow-up
Description: STX-015-18-01 long-term safety follow-up
Study: NCT03150290

Intervention type: OTHER
Group type: OTHER
Intervention: Indirect Calorimetry.
Description: REE measurement

Intervention type: OTHER
Group type: OTHER
Intervention: Indirect Calorimetry.
Description: REE measurement

Intervention type: DEVICE
Group type: OTHER
Intervention: 18-FDG-PET
Description: 18-FDG-PET

Intervention type: DEVICE
Group type: OTHER
Intervention: 18-FDG-PET
Description: 18-FDG-PET
Study: NCT02689206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
Study: NCT03174561

Intervention type: OTHER
Group type: OTHER
Intervention: diet restriction
Description: diet restriction for 28 days
Study: NCT02011672

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutrient-enriched milk

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: regular milk
Study: NCT00032006

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study: NCT02789020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: functional Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.
Study: NCT00032006

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03990701

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 11C-Metomidate PET/CT Scan
Description: 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre
Study: NCT04209400

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac®
Description: Sci-B-Vac® vaccine-10 μg of HBsAg, intramuscular injection of 10 μg/ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B®
Description: Engerix-B® vaccine-20 μg of HBsAg, intramuscular injection of 20 μg/ml
Study: NCT02808507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TB case finding
Description: Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active TB case finding
Description: Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
Study: NCT03862495

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C. trachomatis and N. gonorrhoeae
Description: In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.
Study: NCT02789020

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional Magnetic Resonance Imaging
Description: This test will be performed at baseline and one year.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Function Performance Test
Description: This test will be performed at baseline and one year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Function Performance Test
Description: This test will be performed at baseline and one year.
Study: NCT03771352

Intervention type: DEVICE
Group type: OTHER
Intervention: RxSight RxLAL
Description: The patients will be assessed for 6 months
Study: NCT03438903

Intervention type: DEVICE
Intervention: Repeat exams of OCT device
Description: All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices

Intervention type: DEVICE
Intervention: Repeat exams of OCT device
Description: All 2 consecutive OCT examinations were performed by 1 experienced technician, in the order of SD-OCT and SS-OCT. The interval was 10 minutes between examinations by each OCT devices
Study: NCT00445315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 300 mg BID
Study: NCT03862495

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: C. trachomatis and N. gonorrhoeae
Description: In vitro nucleic acid amplification test for the qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhea in patient specimens utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the detection of C. trachomatis and N. gonorrhoeae.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1g administered as a single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1g administered as a single oral dose
Study: NCT02689206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863
Description: GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1278863 matching Placebo
Description: GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
Study: NCT01239277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein
Description: 20g protein
Study: NCT03862495

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Partner notification and treatment
Description: Pregnant women who test positive for Chlamydia will also be suggested to take Azithromycin home to treat their spouses
Study: NCT00445315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 450 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 100 mg BID
Study: NCT00437203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00477736
Description: * Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).~* If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion.
Study: NCT00445315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00868554
Description: 300 mg TID
Study: NCT00437203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
Study: NCT02733679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
Study: NCT04785937

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound and Magnetic Resonance
Description: liver ultrasound (US), including shear wave elastography (SWE) with liver stiffness measurement and US- fatty liver indicator (US-FLI), and a multiparametric unenhanced liver magnetic resonance examination including MR spectroscopy (MRS), Proton Density Fat Fraction (PDFF) and T2\* measurement with Multiecho technique, T1 mapping with Inversion Recovery method, and Intravoxel Incoherent Motion diffusion weighted imaging (IVIM-DWI), measuring different parameters.
Study: NCT02661945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near focus with narrow band imaging
Study: NCT00445315

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03285386

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming exercise
Description: All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercise
Description: All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
Study: NCT01239277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and carbohydrate
Description: 20g protein and 20g carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and carbohydrate
Description: 20g protein and 20g carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: protein and leucine
Description: 20g protein, 2.5g leucine
Study: NCT02534012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Description: Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Major abdominal surgery
Study: NCT00707538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS747158
Description: 2 IV injection of \~11 mCi (total) F-18 labeled compound
Study: NCT00084604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies